Amicus Therapeutics Inc. (NASDAQ:FOLD) shares fell 2.8% on Friday . The company traded as low as $5.87 and last traded at $6.00, with a volume of 1,233,189 shares trading hands. The stock had previously closed at $6.17.

FOLD has been the subject of a number of recent analyst reports. Leerink Swann reiterated an “outperform” rating and issued a $17.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, June 1st. Bank of America Corp. initiated coverage on shares of Amicus Therapeutics in a research note on Wednesday, May 18th. They issued a “buy” rating and a $10.00 price target for the company. Robert W. Baird initiated coverage on shares of Amicus Therapeutics in a research note on Wednesday, April 13th. They issued a “neutral” rating and a $9.00 price target for the company. Goldman Sachs Group Inc. initiated coverage on shares of Amicus Therapeutics in a research note on Wednesday, March 30th. They issued a “neutral” rating and a $10.00 price target for the company. Finally, Chardan Capital increased their price target on shares of Amicus Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, April 12th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Amicus Therapeutics has a consensus rating of “Buy” and an average price target of $12.88.

The firm has a 50-day moving average of $6.32 and a 200-day moving average of $7.15. The firm’s market cap is $762.29 million.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.01. Analysts forecast that Amicus Therapeutics Inc. will post ($1.35) EPS for the current year.

In other Amicus Therapeutics news, General Counsel Ellen Rosenberg purchased 15,000 shares of Amicus Therapeutics stock in a transaction on Thursday, June 2nd. The shares were acquired at an average cost of $7.67 per share, for a total transaction of $115,050.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Other hedge funds and institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors boosted its position in shares of Amicus Therapeutics by 1.7% in the fourth quarter. Nationwide Fund Advisors now owns 105,597 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 1,754 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of Amicus Therapeutics by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 117,318 shares of the biopharmaceutical company’s stock valued at $1,138,000 after buying an additional 15,789 shares in the last quarter. Swiss National Bank boosted its position in shares of Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock valued at $1,360,000 after buying an additional 5,100 shares in the last quarter. TD Asset Management Inc. boosted its position in shares of Amicus Therapeutics by 1.5% in the fourth quarter. TD Asset Management Inc. now owns 178,700 shares of the biopharmaceutical company’s stock valued at $1,733,000 after buying an additional 2,600 shares in the last quarter. Finally, Columbus Circle Investors boosted its position in shares of Amicus Therapeutics by 122.7% in the fourth quarter. Columbus Circle Investors now owns 227,889 shares of the biopharmaceutical company’s stock valued at $2,211,000 after buying an additional 125,574 shares in the last quarter.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.